Skip to main content

Es können sowohl bereits publizierte oder zur Veröffentlichung akzeptierte Arbeiten eingereicht werden als auch solche, die als Vortrag auf der nächsten Jahrestagung der Deutschen Gesellschaft für Urologie vorgestellt werden. Für Publikationen gilt, dass diese in Fachzeitschriften mit peer-review erfolgen müssen und nicht älter als zwei Jahre sein dürfen.

Dieser Preis ist mit 7.500 Euro dotiert. 

Über die Preisvergabe entscheidet eine Jury.

Ende der Einreichungsfrist: 1. Juni.

Preisträger*innen

2025
Dr. Gregor Duwe, Mainz
„Development of an artificial intelligence-generated explainable treatment recommendation system für urothelial carcinoma and renal cell carcinoma to support multidisciplinary cancer conferences“

2024
Dr. med. Gamal Anton Wakileh, Ulm
„Molecular characterization of the CXCR4 / CXCR7 axis in germ cell tumors and its targetability using nanobody-drug-conjugates“

PD Dr. med. habil. Markus Eckstein, Erlangen
„SpatialImmunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint Inhibition“

2023
Dr. Niklas Klümper, Bonn
„Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance“

2022
Dr. Victor Schüttfort, Hamburg
„Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes after Radical Cystectomy“

2019
PD Dr. med. Wolfgang Fendler, Essen
„Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer – A Prospective Single-Arm Clinical Trial”

2018
Martin Puhr, Innsbruck, Österreich
„The glucocorticoid receptor is a key player for prostate cancer cell survival and a target for improved anti-androgen therapy”

2017
PD Dr. Tobias Maurer, München
„Value of 111In-prostate-specific membrane antigen (PSMA)-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up”

2016
Dr. Renate Pichler, Innsbruck
„Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical bacillus calmette-guérin therapy in bladder cancer”

2015
PD Dr. Jörg Ellinger, Bonn
„Identification of novel long non-coding RNAs in clear cell renal cell carcinoma”

2014
J. Heinzelmann, Homburg/Saar
„MicroRNAs with Prognostic Potential for Metastasis in Clear Cell Renal Cell Carcinoma: A Comparison of Primary Tumors and Distant Metastases”

W. Jager, Mainz
„Ultrasound-guided intramural inoculation of orthotopic bladder cancer xenografts: a novel high-precision approach”

2013
Heidegger, I., Innsbruck
„Diverse Functions of IGF/Insulin Signaling in Malignant and Noncancerous Prostate Cells: Proliferation in Cancer Cells and Differentiation in Noncancerous Cells”

2012
Hofer, J., Innsbruck
„PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21”

2011
Ohlmann, C.-H., Markert, E., Gerharz, M., Dienes, H.-P., Stockle, M., Engelmann, U., Heidenreich, A.
„Improving the Efficacy of Targeted Trials by Multiple-marker Analysis in Castrationresistant Prostate Cancer”

Roos, F., R., Roberts, A. M., Hwang, I. L., Moriyama, E. H., Evans, A. J., Sybingco, S., Warson, I. R., Carneiro, L. A. M., Gedye, C., Girardin, S., E., Ailles, L. E., Jewett, M. A S., Milosevic, M., Wilson, B. C., Bell, J. C., Der, S. D., Ohh, M.
„Oncolytic Targeting of Renal Cell Carcinoma via Encephalomyocarditis Virus”

2010
Kruck, S., Bedke, J., Hennenlotter, J., Ohneseit, P.A., Kuehs, U., Senger, E., Sievert, K.-D., Stenzl, A.
„Activation of mTOR in renal cell carcinoma is due to increased phosphorylation rather than protein overexpression”

2009
Tezval, H., Hannover
„Urocortin and corticotropin releasing factor receptor 2 in human renal cell carcinoma: disruption of an endogenous inhibitor of angiogenesis and proliferation”

2008
Grünwald, V., De Graffenried, L., Russel, D., Friedrichs, W.E., Ray, R.B., Hidalgo, M., Hannover
„Inhibitors of m TOR Reverse Doxorubicin Resistance Conferred by PTEN Status in Prostate Cancer Cells”